Non-interventional, real-world study of patients with early stage, human epidermal growth factor receptor 2 (HER2) positive breast cancer (BC) receiving Trazimera (VESTA)

19/12/2019
19/12/2019
EU PAS number:
EUPAS32829
Study
Planned
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

Pfizer B3271014 Trazimera Real World Evidence Protocol v1 05Sep2019

English (1014.52 KB - PDF) View document
Study results
Study report
Other information